April 01, 2010 Archives - Renal and Urology News

Print Issue: April 01, 2010

FDA Clears a Six-Month Trelstar Formulation

Watson Pharmaceuticals has received FDA approval of Trelstar (triptorelin pamoate for injectable suspension) 22.5 mg, the first and only six-month intramuscular gonadotropin releasing hormone (GnRH) agonist for the palliative treatment of advanced prostate cancer.

Small Renal Masses Are Overtreated

SAN FRANCISCO—Active surveillance of small renal masses (SRMs) may be an appropriate approach for many patients, especially older individuals and those with comorbidities that would complicate treatment or reduce life expectancy, according to Michael Jewett, MD, of Princess Margaret Hospital and the University of Toronto.

Next post in Malpractice News